

Eric Hollander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9190196/publications.pdf>

Version: 2024-02-01

126
papers

10,286
citations

38742

50
h-index

34986

98
g-index

128
all docs

128
docs citations

128
times ranked

7892
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2022, 149, 367-373. | 3.1 | 7 |
| 2 | The Montefiore-Einstein Rigidity Scale-Revised (MERS-R): Development, administration, reliability, and validity in child and adult Autism Spectrum Disorder (ASD). <i>Journal of Psychiatric Research</i> , 2022, 147, 142-147. | 3.1 | 2 |
| 3 | The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. <i>Comprehensive Psychiatry</i> , 2022, 116, 152315. | 3.1 | 9 |
| 4 | Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 233-241. | 1.3 | 1 |
| 5 | Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., <i>JAMA Psychiatry</i> . 2022;79(3):193-200 (1). <i>Comprehensive Psychiatry</i> , 2022, 116, 152323. | 3.1 | 0 |
| 6 | Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. <i>Molecular Autism</i> , 2022, 13, . | 4.9 | 10 |
| 7 | Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder. <i>JAMA Psychiatry</i> , 2022, 79, 760. | 11.0 | 22 |
| 8 | Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial. <i>Journal of Psychiatric Research</i> , 2021, 137, 643-651. | 3.1 | 29 |
| 9 | Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 115-131. | 2.4 | 27 |
| 10 | Challenges in assessing change in autistic adults: scale limitations and discrepancies in reporting in clinical trials. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, , 1-5. | 2.4 | 0 |
| 11 | Potential of cannabinoids as treatments for autism spectrum disorders. <i>Journal of Psychiatric Research</i> , 2021, 137, 194-201. | 3.1 | 8 |
| 12 | Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. <i>International Clinical Psychopharmacology</i> , 2021, 36, 61-75. | 1.7 | 27 |
| 13 | Randomized crossover feasibility trial of helminthic <i>Trichuris suis</i> ova versus placebo for repetitive behaviors in adult autism spectrum disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 291-299. | 2.6 | 13 |
| 14 | Clinical characteristics and comorbidity associated with female gender in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2020, 131, 209-214. | 3.1 | 9 |
| 15 | NeuroCOVID-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. <i>Journal of Psychiatric Research</i> , 2020, 130, 215-217. | 3.1 | 25 |
| 16 | Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. <i>International Clinical Psychopharmacology</i> , 2020, 35, 173-193. | 1.7 | 70 |
| 17 | Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1211-1219. | 1.8 | 8 |
| 18 | Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. <i>Frontiers in Behavioral Neuroscience</i> , 2019, 13, 70. | 2.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Early intervention for obsessive compulsive disorder: An expert consensus statement. <i>European Neuropsychopharmacology</i> , 2019, 29, 549-565. | 0.7 | 92 |
| 20 | Pharmacological Treatment of Body Dysmorphic Disorder. <i>Current Neuropharmacology</i> , 2019, 17, 697-702. | 2.9 | 14 |
| 21 | New perspectives in the treatment of body dysmorphic disorder. <i>F1000Research</i> , 2018, 7, 361. | 1.6 | 16 |
| 22 | From Treatment Response to Recovery: A Realistic Goal in OCD. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1007-1013. | 2.1 | 20 |
| 23 | Are there new advances in the pharmacotherapy of autism spectrum disorders?. <i>World Psychiatry</i> , 2017, 16, 101-102. | 10.4 | 10 |
| 24 | An expert opinion on PANDAS/PANS: highlights and controversies. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 91-98. | 2.4 | 43 |
| 25 | Body Dysmorphic Disorder in Patients With Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus. <i>American Journal of Psychiatry</i> , 2017, 174, 313-316. | 7.2 | 12 |
| 26 | Oxytocin and Prader-Willi Syndrome. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 35, 529-557. | 1.7 | 18 |
| 27 | Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 131-136. | 2.4 | 12 |
| 28 | A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 1914-1923. | 5.4 | 63 |
| 29 | Behavioral phenotype in a child with Prader-Willi syndrome and comorbid 47, XYY. <i>Intractable and Rare Diseases Research</i> , 2016, 5, 235-237. | 0.9 | 1 |
| 30 | Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient Outcomes) trial. <i>Journal of the Neurological Sciences</i> , 2016, 365, 190-198. | 0.6 | 19 |
| 31 | Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial. <i>Journal of Psychopharmacology</i> , 2016, 30, 568-578. | 4.0 | 30 |
| 32 | Standards of care for obsessive-compulsive disorder centres. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 204-208. | 2.4 | 12 |
| 33 | Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 210-217. | 2.4 | 50 |
| 34 | New treatment models for compulsive disorders. <i>European Neuropsychopharmacology</i> , 2016, 26, 877-884. | 0.7 | 17 |
| 35 | The cost and impact of compulsivity: A research perspective. <i>European Neuropsychopharmacology</i> , 2016, 26, 800-809. | 0.7 | 105 |
| 36 | Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 174-186. | 2.6 | 148 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , 2015, 20, 469-473. | 1.2 | 18 |
| 38 | Catalysts for Change: The Role of Small Business Funders in the Creation and Dissemination of Innovation. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 3900-3904. | 2.7 | 6 |
| 39 | Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 368-375. | 2.6 | 4 |
| 40 | Management of Obsessive-Compulsive Disorder. <i>F1000prime Reports</i> , 2014, 6, 68. | 5.9 | 28 |
| 41 | Compulsivity, impulsivity, and the DSM-5 process. <i>CNS Spectrums</i> , 2014, 19, 62-68. | 1.2 | 86 |
| 42 | Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. <i>Journal of Psychopharmacology</i> , 2014, 28, 596-602. | 4.0 | 55 |
| 43 | Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 948-957. | 2.7 | 62 |
| 44 | Pathological gambling treated with lithium: The role of assessing temperament. <i>Addictive Behaviors</i> , 2014, 39, 1911-1913. | 3.0 | 6 |
| 45 | Comorbidity in obsessive-compulsive disorder (OCD): A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>Comprehensive Psychiatry</i> , 2014, 55, 1513-1519. | 3.1 | 105 |
| 46 | rTMS in resistant mixed states: An exploratory study. <i>Journal of Affective Disorders</i> , 2014, 157, 66-71. | 4.1 | 18 |
| 47 | Compulsivity and impulsivity—personal reflections: why now and why here?. <i>CNS Spectrums</i> , 2014, 19, 6-7. | 1.2 | 4 |
| 48 | The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome. <i>Current Neuropharmacology</i> , 2014, 12, 71-98. | 2.9 | 65 |
| 49 | The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>European Neuropsychopharmacology</i> , 2013, 23, 865-871. | 0.7 | 53 |
| 50 | Effects of age and symptomatology on cortical thickness in autism spectrum disorders. <i>Research in Autism Spectrum Disorders</i> , 2013, 7, 141-150. | 1.5 | 55 |
| 51 | Baseline Factors Predicting Placebo Response to Treatment in Children and Adolescents With Autism Spectrum Disorders. <i>JAMA Pediatrics</i> , 2013, 167, 1045. | 6.2 | 49 |
| 52 | Social Synchrony and Oxytocin: From Behavior to Genes to Therapeutics. <i>American Journal of Psychiatry</i> , 2013, 170, 1086-1089. | 7.2 | 7 |
| 53 | A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. <i>American Journal of Psychiatry</i> , 2012, 169, 292-299. | 7.2 | 169 |
| 54 | Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. <i>Molecular Autism</i> , 2012, 3, 16. | 4.9 | 293 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | The 5-HT 2A receptor and serotonin transporter in Asperger's Disorder: A PET study with [11 C]MDL 100907 and [11 C]DASB. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 230-234. | 1.8 | 41 |
| 56 | Factor Analysis of Repetitive Behaviors in Autism as Measured by the Y-BOCS. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 332-339. | 1.8 | 20 |
| 57 | Non-Paraphilic Compulsive Sexual Behavior and Psychiatric Co-morbidities in Gay and Bisexual Men. <i>Sexual Addiction and Compulsivity</i> , 2011, 18, 114-134. | 0.9 | 24 |
| 58 | Quality of Life Outcomes in Patients With Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 784-792. | 2.2 | 82 |
| 59 | Autism and Oxytocin: New Developments in Translational Approaches to Therapeutics. <i>Neurotherapeutics</i> , 2010, 7, 250-257. | 4.4 | 123 |
| 60 | Probing Compulsive and Impulsive Behaviors, from Animal Models to Endophenotypes: A Narrative Review. <i>Neuropsychopharmacology</i> , 2010, 35, 591-604. | 5.4 | 588 |
| 61 | Divalproex Sodium vs Placebo for the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorders. <i>Neuropsychopharmacology</i> , 2010, 35, 990-998. | 5.4 | 179 |
| 62 | Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior. <i>Archives of General Psychiatry</i> , 2009, 66, 583. | 12.3 | 416 |
| 63 | Neurological considerations: Autism and Parkinson's disease. <i>Psychiatry Research</i> , 2009, 170, 43-51. | 3.3 | 25 |
| 64 | Cross-cutting issues and future directions for the OCD spectrum. <i>Psychiatry Research</i> , 2009, 170, 3-6. | 3.3 | 61 |
| 65 | Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. <i>Depression and Anxiety</i> , 2008, 25, 317-329. | 4.1 | 87 |
| 66 | Autism-related routines and rituals associated with a mitochondrial aspartate/glutamate carrier SLC25A12 polymorphism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 408-410. | 1.7 | 51 |
| 67 | Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. <i>Body Image</i> , 2008, 5, 13-27. | 4.3 | 174 |
| 68 | Psychopharmacologic Interventions for Repetitive Behaviors in Autism Spectrum Disorders. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2008, 17, 753-771. | 1.9 | 55 |
| 69 | FDG-PET Study in Pathological Gamblers. <i>Neuropsychobiology</i> , 2008, 58, 37-47. | 1.9 | 45 |
| 70 | An Open-Label Trial of Venlafaxine in Body Dysmorphic Disorder. <i>CNS Spectrums</i> , 2008, 13, 138-144. | 1.2 | 40 |
| 71 | The Consequences of Compulsive Sexual Behavior: The Preliminary Reliability and Validity of the Compulsive Sexual Behavior Consequences Scale. <i>Sexual Addiction and Compulsivity</i> , 2007, 14, 207-220. | 0.9 | 32 |
| 72 | Anxiety and OC spectrum disorders over life cycle. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 5-10. | 2.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Oxytocin Increases Retention of Social Cognition in Autism. <i>Biological Psychiatry</i> , 2007, 61, 498-503. | 1.3 | 632 |
| 74 | Lack of Evidence for Association of the Serotonin Transporter Gene SLC6A4 with Autism. <i>Biological Psychiatry</i> , 2006, 60, 186-191. | 1.3 | 48 |
| 75 | Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2006, 21, 189-191. | 1.7 | 53 |
| 76 | Liquid Fluoxetine versus Placebo for Repetitive Behaviors in Childhood Autism. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2006, 1, 105-113. | 0.0 | 2 |
| 77 | Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2006, 21, 363-367. | 1.7 | 114 |
| 78 | Association analysis of the NrCAM gene in autism and in subsets of families with severe obsessive-compulsive or self-stimulatory behaviors. <i>Psychiatric Genetics</i> , 2006, 16, 251-257. | 1.1 | 60 |
| 79 | Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 209. | 2.1 | 126 |
| 80 | A Double-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive Developmental Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 541-548. | 1.3 | 171 |
| 81 | Neurological Soft Signs as Predictors of Treatment Response to Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2005, 17, 472-477. | 1.8 | 34 |
| 82 | Pharmacological Treatments of Pathological Gambling. <i>Journal of Gambling Studies</i> , 2005, 21, 99-108. | 1.6 | 53 |
| 83 | Obsessive-compulsive disorder and spectrum across the life span. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 79-86. | 2.4 | 46 |
| 84 | A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive Behaviors in Childhood and Adolescent Autism. <i>Neuropsychopharmacology</i> , 2005, 30, 582-589. | 5.4 | 364 |
| 85 | Impact of Trait Impulsivity and State Aggression on Divalproex Versus Placebo Response in Borderline Personality Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 621-624. | 7.2 | 168 |
| 86 | Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2727-2740. | 1.8 | 18 |
| 87 | Does Sustained-Release Lithium Reduce Impulsive Gambling and Affective Instability Versus Placebo in Pathological Gamblers With Bipolar Spectrum Disorders?. <i>American Journal of Psychiatry</i> , 2005, 162, 137-145. | 7.2 | 191 |
| 88 | Imaging monetary reward in pathological gamblers. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 113-120. | 2.6 | 52 |
| 89 | Striatal Volume on Magnetic Resonance Imaging and Repetitive Behaviors in Autism. <i>Biological Psychiatry</i> , 2005, 58, 226-232. | 1.3 | 352 |
| 90 | Impact of Recent Findings on Study Design of Future Autism Clinical Trials. <i>CNS Spectrums</i> , 2004, 9, 49-56. | 1.2 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Beyond refractory obsessions and anxiety states: toward remission. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 14, 3-5. | 2.2 | 3 |
| 92 | Diagnosis and treatment of pathologic gambling. <i>Current Psychiatry Reports</i> , 2003, 5, 9-15. | 4.5 | 38 |
| 93 | Targeted treatments for symptom domains in child and adolescent autism. <i>Lancet, The</i> , 2003, 362, 732-734. | 13.7 | 79 |
| 94 | Obsessive-compulsive behaviors in parents of multiplex autism families. <i>Psychiatry Research</i> , 2003, 117, 11-16. | 3.3 | 122 |
| 95 | Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 193-198. | 5.4 | 632 |
| 96 | A Double-Blind, Placebo-Controlled Trial of Clonazepam in Obsessive-Compulsive Disorder. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 30-34. | 2.6 | 61 |
| 97 | Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 1186-1197. | 5.4 | 231 |
| 98 | Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 397-401. | 2.1 | 166 |
| 99 | Obsessive-Compulsive Spectrum Disorders: A Review. , 2003, , 203-252. | | 6 |
| 100 | Obsessive-compulsive spectrum disorders. <i>Dialogues in Clinical Neuroscience</i> , 2003, 5, 259-271. | 3.7 | 24 |
| 101 | Venlafaxine in Treatment-Resistant Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 546-550. | 2.2 | 51 |
| 102 | A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Controlled-Release Fluvoxamine in Patients With Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 640-647. | 2.2 | 73 |
| 103 | Acute and Long-Term Treatment and Prevention of Relapse of Obsessive-Compulsive Disorder With Paroxetine. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1113-1121. | 2.2 | 107 |
| 104 | Treatment non-response in OCD: methodological issues and operational definitions. <i>International Journal of Neuropsychopharmacology</i> , 2002, 5, 181-91. | 2.1 | 325 |
| 105 | Symptom domains in autism and related conditions: Evidence for familiarity. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 64-73. | 2.4 | 111 |
| 106 | Diagnosis and treatment of body dysmorphic disorder in adolescents. <i>Current Psychiatry Reports</i> , 2002, 4, 108-113. | 4.5 | 18 |
| 107 | Lithium and Valproate Treatment of Pathological Gambling. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 559-564. | 2.2 | 122 |
| 108 | Refractory obsessive-compulsive disorder: state-of-the-art treatment. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 6, 20-9. | 2.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Obsessive-Compulsive Spectrum Disorders: A Review. , 2001, , 203-252. | | 10 |
| 110 | Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. International Journal of Neuropsychopharmacology, 2001, 4, 119-25. | 2.1 | 100 |
| 111 | Hypothalamic-pituitary-adrenal Axis Dysregulation in Depersonalization Disorder. Neuropsychopharmacology, 2001, 25, 793-795. | 5.4 | 47 |
| 112 | An Open Trial of Divalproex Sodium in Autism Spectrum Disorders. Journal of Clinical Psychiatry, 2001, 62, 530-534. | 2.2 | 187 |
| 113 | Limbic Circuitry in Patients With Autism Spectrum Disorders Studied With Positron Emission Tomography and Magnetic Resonance Imaging. American Journal of Psychiatry, 2000, 157, 1994-2001. | 7.2 | 354 |
| 114 | PATHOLOGICAL GAMBLING. Psychiatric Clinics of North America, 2000, 23, 629-642. | 1.3 | 78 |
| 115 | BODY DYSMORPHIC DISORDER. Psychiatric Clinics of North America, 2000, 23, 617-628. | 1.3 | 24 |
| 116 | Clomipramine vs Desipramine Crossover Trial in Body Dysmorphic Disorder. Archives of General Psychiatry, 1999, 56, 1033. | 12.3 | 256 |
| 117 | SSRIs in the Treatment of obsessive-compulsive disorder. Depression and Anxiety, 1998, 8, 105-113. | 4.1 | 41 |
| 118 | Short-Term Single-Blind Fluvoxamine Treatment of Pathological Gambling. American Journal of Psychiatry, 1998, 155, 1781-1783. | 7.2 | 216 |
| 119 | A Dimensional Approach to the Autism Spectrum. CNS Spectrums, 1998, 3, 22-39. | 1.2 | 31 |
| 120 | Psychosocial Function and Economic Costs of Obsessive-Compulsive Disorder. CNS Spectrums, 1998, 3, 48-58. | 1.2 | 34 |
| 121 | SSRIs in the Treatment of obsessive-compulsive disorder. Depression and Anxiety, 1998, 8, 105-113. | 4.1 | 6 |
| 122 | The obsessive-compulsive spectrum disorders. International Review of Psychiatry, 1997, 9, 99-110. | 2.8 | 76 |
| 123 | Sexual Dysfunction Associated with the Drug Treatment of Psychiatric Disorders. CNS Drugs, 1994, 2, 78-86. | 5.9 | 20 |
| 124 | Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. , 0, , 105-114. | | 1 |
| 125 | Psychobiology of Impulse-Control Disorders Not Otherwise Specified (NOS). , 0, , 1315-1329. | | 0 |
| 126 | Psychotropic Treatment of Autism. Key Issues in Mental Health, 0, , 151-165. | 0.6 | 3 |